Tesamorelin was studied at 26 weeks and extended to 52. It is not run as a cycle. It is continuous prescription therapy, and the visceral fat it removes returns once the drug is stopped.
The phrase "cycle length" imports a bodybuilding frame that does not fit tesamorelin. It is a prescription GHRH analog taken continuously within its approved indication, not a fixed block you run and drop. The trials ran 26 weeks [2] and extended to 52 weeks [3], and the useful question is not how long to cycle but how long a prescriber keeps you on it against your labs.
- Trial durations were 26 weeks, extended to 52, with visceral fat reduction maintained through a year [2][3]
- Visceral fat reaccumulates after discontinuation [4]
- It is not cycled like an anabolic steroid. The GHRH-analog mechanism has no HPTA to recover [1]
- The label directs monitoring IGF-1 and reassessing continued need, not a preset stop date [1]
- For the off-label age-related goal, compounded sermorelin is judged on a 90-day IGF-1 retest and a 6-month evaluation
What the Trials Actually Ran
The registration program gives the only durations with data behind them. The registration trials measured the primary visceral fat endpoint at 26 weeks [2], then carried a subset to 52 weeks in safety extensions. The pooled analysis found the visceral fat treatment effect was 15.4% at 26 weeks and 17.5% at 52 weeks [3], so the benefit held and modestly increased across a full year of continuous use.
There is no trial-supported "8-week cycle" or "12-week block." The evidence describes continuous daily dosing measured at 6 months and 12 months. Any shorter fixed course is extrapolation past the data.
How Long Before It Works
The primary outcome was assessed at 26 weeks, and that is the honest timeline for the visceral fat effect. IGF-1 moves earlier, since IGF-1 rose 81.0% over the 26-week trial [2] and the biochemical response precedes the body composition change. A 6-month assessment is the reasonable point to judge whether the fat loss is materializing.
IGF-1 is the marker that tells you the axis is being driven before visceral fat has visibly moved. Drawing it partway through the course is how a prescriber confirms the drug is doing something rather than waiting the full 6 months on faith.
What Happens When You Stop
This is the fact that makes "cycle" the wrong model. When tesamorelin is discontinued, visceral fat reaccumulates [4]. It suppresses visceral fat accumulation while taken and does not lock in the result. A cycle implies you finish and keep the gains. Here, stopping reverses the primary benefit.
Why It Is Not Cycled Like a Steroid
Anabolic cycling exists to manage receptor downregulation and to let a suppressed hypothalamic-pituitary-gonadal axis recover between blocks. None of that logic applies here. Tesamorelin is a GHRH analog acting on the pituitary under intact somatostatin feedback, so the pituitary is not suppressed the way exogenous hormone suppresses its own axis. There is no downstream axis to restart, which is why the label frames therapy as ongoing rather than as intervals.
The prescribing information directs clinicians to monitor IGF-1 during therapy and to reassess the continued need for the drug periodically [1], not to run a fixed number of weeks and stop. Duration is a clinical decision reviewed against labs and response, not a preset block.
Monitoring Across the Course
- Baseline IGF-1 before the first dose, interpreted against the age-adjusted range
- Monitor IGF-1 during therapy and treat a persistent elevation above range as a reason to reduce dose or stop [1]
- Check glucose in the first 3 months, since growth hormone opposes insulin, though pooled data showed neutrality by 52 weeks and the early HbA1c rise resolved [3][5]
- Judge the visceral fat outcome at roughly 6 months, when the primary endpoint was measured [2]
- Reassess continued need rather than assuming an indefinite run
Duration for the Off-Label Goal
Most people searching this are not on tesamorelin for lipodystrophy. They want a GHRH analog for age-related decline, where the drug telehealth actually prescribes is compounded sermorelin. The duration logic is the same shape: a baseline IGF-1, a 90-day retest when the response approaches peak, and a 6-month window before a verdict. Sermorelin raises IGF-1 within 2 weeks of correct nightly dosing [6], and it is dosed nightly rather than cycled, for the same reason tesamorelin is not.
Tesamorelin is not run as a fixed cycle, and neither is the compounded sermorelin most people are actually prescribed for age-related decline. SystemLabs tests IGF-1 before prescribing and rechecks at 90 days, so how long you stay on is a lab decision rather than a preset block.
Frequently Asked Questions
How long is a tesamorelin cycle?
Tesamorelin is not cycled. It is continuous prescription therapy studied at 26 weeks and extended to 52 [2][3]. There is no trial-supported fixed cycle length. The duration is set by a prescriber against IGF-1 and clinical response, and the label directs reassessing continued need rather than running a preset block [1].
What happens when you stop tesamorelin?
Visceral fat reaccumulates. The trial data showed the visceral fat reduction reversed after discontinuation [4]. Tesamorelin suppresses visceral fat accumulation while it is taken rather than permanently resetting it, so the benefit is maintained only during continued use.
How long does tesamorelin take to work?
The primary visceral fat endpoint was measured at 26 weeks, so about 6 months is the honest timeline for the fat effect [2]. IGF-1 moves earlier and rose 81% across that 26-week trial [2], which is why an interim IGF-1 draw is used to confirm the axis is responding before the body composition change is visible.
Can you take tesamorelin long term?
The controlled data extends to 52 weeks, where the visceral fat effect was maintained and glucose was neutral [3]. Longer than that is not well characterized in trials. The label frames it as ongoing therapy with IGF-1 monitoring and periodic reassessment of continued need, not a fixed-length course [1].
Is tesamorelin cycled like steroids?
No. Steroid cycling manages receptor downregulation and lets a suppressed gonadal axis recover. Tesamorelin is a GHRH analog acting on the pituitary under intact somatostatin feedback, so the pituitary is not suppressed and there is no downstream axis to restart. Continuous dosing under lab monitoring is the model, not intervals.
How long should you take sermorelin instead?
For the age-related goal tesamorelin is not approved for, compounded sermorelin is the practical GHRH analog. It is dosed nightly, not cycled, and evaluated on a baseline IGF-1, a 90-day retest, and a 6-month window before judging outcomes. The duration is a clinical decision reviewed against labs rather than a fixed block.
References
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: full prescribing information DailyMed, U.S. National Library of Medicine, 2025. FDA-approved labeling. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Journal of Acquired Immune Deficiency Syndromes, 2010. PMID: 20101189. https://pubmed.ncbi.nlm.nih.gov/20101189/
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies Growth Hormone & IGF Research, 2015. PMID: 25555516. https://pubmed.ncbi.nlm.nih.gov/25555516/
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
